Cyclacel's fadraciclib demonstrates efficacy in patient-derived colorectal cancer models at the 2024 asco annual meeting

- novel cdk2/9 inhibitor fadraciclib induces anaphase catastrophe, a novel cancer-specific mechanism of action -

CYCC Ratings Summary

CYCC Quant Ranking